Navigation Links
Transcept Pharmaceuticals Appoints Key Senior Executives
Date:7/2/2008

South Florida and has taken additional executive level courses at the Wharton and Kellogg Schools of Business.

"I am delighted to join the Transcept management team at such an exciting time in the company's development," said Mr. Moore. "Intermezzo(R) has the potential to become an innovative low dose solution for insomnia patients who wake up in the middle of the night and want to go back to sleep quickly. Intermezzo(R) will enable patients to treat their middle of the night awakening only when it occurs, rather than having to take a high dose, 8 hour medication at bedtime. I'm thrilled to be a part of a team dedicated to developing and commercializing innovative neuroscience-based products."

Susan Koppy has over 20 years of experience in marketing and business development in the biopharmaceutical industry and has lived and worked in the U.S., Europe and Japan. She has negotiated a number of major multi-billion dollar agreements and is a frequent speaker on business development issues. Prior to joining Transcept, Susan Koppy served as Senior Vice President, Business and Corporate Development at Idenix Pharmaceuticals, Inc. Previously, Ms. Koppy was Vice President of Strategy and Business Development at Applied Biosystems, Inc. (ABI) with responsibility for evaluation and pursuit of licensing and acquisition opportunities. Before joining ABI, Ms. Koppy served as the Director of Business Development for Novartis Pharmaceuticals Corporation where she was responsible for global business development opportunities in Infectious Diseases and was a key contributor to the formation of the strategic alliance between Idenix and Novartis. Ms. Koppy also served as the Head of Commercial and Business Intelligence for Novartis Pharma AG and worked in Early Commercial Development with the Respiratory and Immunology therapeutic areas. She holds a bachelor's degree in Genetics and Cell Biology from the University of Minnesota.

"I am excited to join a team of exe
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Transcept Pharmaceuticals to Participate in Middle-of-the-Night (MOTN) Insomnia Investor Panel
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014 OTC Markets Group ... a biotechnology company, on its approval to list ... on OTCQX®, the best marketplace for established U.S. ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... execution of its growth strategy and achievement of ...
(Date:8/21/2014)... August 21, 2014 Pursuit Solutions ... optimization technology and services for Life Sciences sales ... Pharma’s Use of New Commercial Sales Models” by ... Analytics. , The article examines some innovative models ... are being tested in the pharmaceutical market. Robinson ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 ... has been recognized as one of the nation’s ... 5000 magazine for the 2nd consecutive year. Inc. ... 33rd annual Inc. 500|5000, an exclusive ranking of ... the most comprehensive look at the most important ...
(Date:8/20/2014)... patented university inventions licensed to biotechnology firms has ... To open these roadblocks, the researchers suggest that ... discovery stage could lead to faster commercialization down ... from discoveries made in university laboratories and licensed ... clinical trials, which have a high failure rate. ...
Breaking Biology Technology:OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3
... A new anti-sliding adhesive developed by engineers at the University ... to mimic the remarkable gecko toe hairs that allow the ... The researchers say that such an adhesive could one day ... up walls. , Taking a cue from the millions of ...
... to $0.72 on 19.8% Revenue Growth -, PRINCETON, ... earnings for its fourth quarter ended December 31, 2007,of ... both periods include,a $0.06 per share gain from the ... sale, earnings were $0.72 per diluted share in the,fourth ...
... 30 John Wagner, M.D., recognized as,a leader in ... joined,the team at CORD:USE Cord Blood Bank. Dr. Wagner,s ... biology will provide a,significant contribution to CORD:USE., "We,re ... of our,distinguished team," says Edward Guindi, M.D., President and ...
Cached Biology Technology:New adhesive mimics gecko toe hairs 2New adhesive mimics gecko toe hairs 3Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 2Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 3Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 4Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 5Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 6Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 7Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 8Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 9Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 10Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 11CORD:USE Cord Blood Bank Announces the Addition of Dr. John Wagner, a Pioneer in the Use of Umbilical Cord Blood Stem Cells, to Its Scientific Advisory Board 2CORD:USE Cord Blood Bank Announces the Addition of Dr. John Wagner, a Pioneer in the Use of Umbilical Cord Blood Stem Cells, to Its Scientific Advisory Board 3
(Date:8/21/2014)... New feeding tube connectors, designed by an international standards ... safety. , According to an invited review published in ... ( NCP ), the official journal of the ... new connectors will greatly reduce the occurrence of misconnection ... , Small-bore connectors, which are used to join medical ...
(Date:8/21/2014)... Researchers from North Carolina State University have developed a ... The model has applications for creating new materials as ... , "Our new technique allows us to model much ... so much more quickly," says Nan Li, lead author ... student in NC State,s Department of Materials Science and ...
(Date:8/20/2014)... of 158 pregnant teenagers in Rochester, NY, nearly half ... of ice, cornstarch, vacuum dust, baby powder and soap, ... , Moreover, such teens had significantly lower iron levels ... substances. , Pregnant teens, regardless of pica, are at ... iron deficiency and anemia. Low iron in pregnant teens ...
Breaking Biology News(10 mins):New feeding tube connectors will improve patient safety 2Researchers develop models to study polyelectrolytes, including DNA and RNA 2Pica in pregnant teens linked to low iron 2
... ,chocolate, cysts for the brown liquid they contain, can ... which can cause ongoing pain and complications. A study ... effective remedy the oral contraceptive pill (OCP). ... from Auckland, New Zealand, highlight a trial published in ...
... L. Rimoin, MD, PhD, FACMG of Cedars-Sinai Medical Center ... Medical Genetics Foundation (ACMGF) second annual Lifetime Achievement Award ... was recognized for his decades of contributions to genetic ... disorders of connective tissue, and for helping to organize ...
... urine drives crayfish into an aggressive sexual frenzy. Researchers ... suggest that a urine-mediated combination of aggressive and ... to mate. Fiona Berry and Thomas Breithaupt from ... urine-based chemical signaling on sexually active crayfish. Breithaupt said, ...
Cached Biology News:Leader in genetics, Dr. David L. Rimoin, receives ACMG Foundation Lifetime Achievement Award 2Leader in genetics, Dr. David L. Rimoin, receives ACMG Foundation Lifetime Achievement Award 3
Rabbit polyclonal to Flagellin ( Abpromise for all tested applications). Antigen: Synthetic peptide from the flagellin C terminal domain of Burkholderia pseudomallei....
This application changes sensitive keywords in an FCS file to remove patient information. It was contributed by Dr. David Miller....
... Killer Cell Receptor-P1, clone 1C10 ... Hybridoma produced by the ... mice immunized (BALB/c X C57BL/6)F1 ... and mouse myeloma cellline. ...
Phospho-SEK1/MKK4 (Thr261) Antibody...
Biology Products: